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inpatient care and drug costs represented about 50% and 27% respectively of over-
all expenses. The increase by 24.4% polytherapy patients mean costs as compared
to monotherapy raised to 72% [IC 95: 44-106%] after adjustment on age, gender and
presence of severe comorbidity. CONCLUSIONS: Polytherapy in epilepsy is associ-
ated with substantial higher direct costs.
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OBJECTIVES: To develop a tool to estimate the first-year per member and total
health plan costs associated with monitoring of MS therapies in the United States.
METHODS: Data were incorporated into an interactive tool designed to allow a
health plan to estimate their costs for monitoring. MS prevalence was based on the
literature. The default value for the proportion of MS patients treated with immu-
nomodulators was assumed at 95% and adjusted IMS data were used for default
market share inputs. Current Procedural Terminology (CPT) codes corresponding
to the monitoring and administration procedures recommended by each product’s
prescribing information (PI) were identified. Charges associated with each CPT
code were assigned using physician fee schedule software based on Medicare
charges with default values set at 150%. PI recommendations were used for the
proportion being monitored and the frequency of monitoring. In cases where a PI
recommended only individuals with specific characteristics undergo monitoring, a
database analysis identifying all individuals with a diagnosis of MS in the i3 InVi-
sion Data Mart (Ingenix, Eden Prairie, MN) was used to estimate the proportion of
patients who may require that specific monitoring. RESULTS: The tool yielded
average per patient and health plan costs expected with MS therapy monitoring.
The tool conservatively estimates that the average per member first-year monitor-
ing and administration costs ranged from $0 for glatiramer acetate to $3279 for
natalizumab. Based on default values, the estimated annual costs of monitoring for
all MS therapies for a million member health plan is $519,451. CONCLUSIONS:
Estimating the economic impact of FDA-recommended MS therapy monitoring
allows health plans to more closely assess the total cost of MS. This tool allows
health plans to individualize inputs to estimate the plan-specific economic impact
of MS therapy monitoring.
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OBJECTIVES: Botulinum toxin A (BTA) injections are indicated for the management
of neurological movement disorders, including arm spasticity (AS) and cervical
dystonia (CD). This study calculated the cost per care episode for two BTA: Botox®
and Dysport®. The analysis was completed for 20 countries around the world.
METHODS: Doses of BTA are expressed in non-interchangeable units: Botox® is
available in “Allergan units” whereas Dysport® is provided in 500 “Speywood
units”. Recommended dosages were derived from country SmPCs/PIs. Cost analy-
sis was based on official list prices and expressed in 2011 euros, using exchange
rates as of end of May 2011. The cost per care episode was calculated using avail-
able recommended dosages for each product (country’s own or average of other
countries) combined with price per vial in each country. RESULTS: For AS, recom-
mended total injection dosage per patient for Dysport is 1000 units in all countries
where indicated in SmPCs; for Botox®, it is 300U per patient based on recom-
mended dosages in the USA and France. For CD, dosages for Dysport® are 500U per
patient; whereas 200U of Botox® is recommended per patient. Considered with the
respective prices per vial in each country, Dysport® cost per patient per care epi-
sode for AS was less than Botox® in 17 (89%) of the 19 countries (average 15% less
across countries). The difference was 20% or higher in nearly half (47%) of coun-
tries. In CD, these differences were even greater with Dysport® cost per patient was
40% or less versus Botox in 45% of countries (average 36% less across countries).
CONCLUSIONS: Considering cost per patient per care episode based on recom-
mended dosages in SmPCs/PIs, Dysport® remains cheaper versus Botox in most
countries. When extrapolated to a national level, substantial savings could be re-
alized by using Dysport® in the treatment of AS and CD.
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OBJECTIVES: The aim of this study was to calculate the incremental cost-effective-
ness ratio of the different Disease Modifying Drugs (DMD) used as first-line treat-
ments (interferons IM IFN-1a, SC IFN-1a, SC IFN-1b and glatiramer acetate, GA)
in Remitting-Relapsing Multiple Sclerosis (RRMS) in Spain. METHODS: A Markov
model was developed to simulate the progression of a cohort of patients with
RRMS, during a period of 10 years. Seven health states, defined by the EDSS, were
considered in the model. Patients with an EDSS score of less than 6.0 were assumed
to be treated with one of DMD. In addition, all patients were assumed to receive
symptomatic treatment. The monthly transition probabilities of the model were
obtained from the literature. The analysis was performed from the societal per-
spective, in which both direct and indirect (losses in productivity) healthcare costs
(€, 2010) were included. A discount rate of 3% was applied to both costs and results.
RESULTS: GA was the less costly strategy (€322,510), followed by IM IFN-1a (€
329.595), SC IFN-1b (€ 333.925) and SC IFN-1a (€ 348.208). IM IFN-1a has
shown the best efficacy results with 4,176 quality-adjusted life year (QALY),
followed by SC IFN-1a (4,158 QALY), SC IFN-1b (4,157 QALY) and GA (4,117
QALY). Incremental costs per QALY gained with IM IFN-1a were €-1,005,194/
QALY, €-223,397/QALY, and €117,914/QALY in comparison to SC IFN-1a, SC
IFN-1b and GA, respectively. CONCLUSIONS: First-line treatment with GA is the
less costly strategy for the treatment of patients with RRMS. Treatment with IM
IFN-1a is a dominant strategy (lower cost and higher QALY) compared with SC
IFN-1a and SC IFN-1b. However, IM IFN-1a is not a cost-effective strategy versus
GA, because incremental cost per QALY gained with IM IFN-1a exceeds the €30,000
per QALY threshold, commonly used in Spain.
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OBJECTIVES: Multiple sclerosis (MS) is the neurologic disability that can dramati-
cally affect the quality of life (QoL) of patients and their families. Family life, eco-
nomic status, and social interaction may be affected by somatic symptoms of the
disease. Approximately 70,000 people in the Islamic Republic of Iran are affected by
MS. Under budgetary constraints,Cost-effectiveness and cost-utility analyses
(CEA/CUAs) are useful tools to assess the tradeoff between the added costs and
potential benefits (e.g., improved patient outcomes) of new therapies. METHODS:
The primary objective of this analysis was to evaluate the cost-effectiveness of
Avonex compared with Betaferon from the Iranian Ministry of Health(MoH) over a
2-year time horizon. The relative risk reduction (RRR) method was used to compare
reduction in relapse rates and disease progression data from pivotal randomized
double-blind placebo-controlled clinical trials of the DMDs. The evaluation was
conducted from the perspective of a Iranian health care sector (direct medical costs
and indirect cost considered). The primary economic endpoint was cost per relapse
avoided . Costs and outcomes occurring in the second year were discounted 3% to
bring to 2010 present values. One way sensitivity analyses were conducted on key
input variables to assess their impact on cost per relapse avoided. RESULTS: The
2-year reductions in clinical relapses for treatment with Avonex,Betaferon were
0.69 and 0.60 relatively. In the base case analysis, Avonex had the most favorable
costs per relapse avoided (2652778 Rials) rather than Betaferon. Sensitivity analy-
ses showed that these results were robust to changes in key input parameters, such
as the number of relapses and disease progression steps in untreated patients, the
progression rates, the average cost of relapse. CONCLUSIONS: This evaluation sug-
gests that IFN -1a SC injection(Avonex) represent the most cost-effective DMDs
for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse
avoided,rather than Bataferon.
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OBJECTIVES: Early intervention in the course of acute migraine attacks has been
recently advocated as a way to further reduce the economic burden and suffering
of patients due to this condition. The aim of this study was to investigate the
cost-effectiveness of such a strategy using almotriptan in the Spanish setting.
METHODS: An economic evaluation was conducted from the Spanish societal and
public health system perspective based on patient-level data collected in the “Act
when Mild” study. Incremental cost-effectiveness ratios (ICER) were determined in
terms of attack duration, loss of productive time and quality-adjusted life days
(QALDs). Monte Carlo simulation was used to derive cost-effectiveness acceptabil-
ity curves. RESULTS: Early treatment led on average to shorter attack duration, less
productive time lost, better quality of life, and was overall cost-saving from a
societal point of view with a probability of 97%. In terms of publicly reimbursed
drug costs only, though, non-early treatment was always slightly less expensive.
From the public health system perspective the (bootstrap) mean ICER of early treat-
ment amounted to €0.12 per migraine hour avoided, €0.42 per hour of productive
time lost avoided, and €6.62 per QALD gained. Considering willingness to pay val-
ues of €1 to reduce attack duration by one hour, €5 to avoid the loss of one produc-
tive hour, or €55 to gain one QALD (equivalent to €20,000 per QALY), the probability
that early treatment was cost-effective from the public health system perspective
was, respectively, 96%, 96%, and 98%. These results remained robust in sensitivity
analyses that accounted for the uncertainty surrounding the major elements of the
economic evaluation. CONCLUSIONS: Compared to non-early treatment, early
treatment of acute migraine attacks with almotriptan when pain is still mild is with
high probability cost-saving from the Spanish societal perspective and cost-effec-
tive from the public health system point of view.
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OBJECTIVES: To estimate the cost-effectiveness of subcutaneously self-adminis-
tered icatibant for the symptomatic treatment of acute attacks of HAE in adults
with C1-INH deficiency.versus current clinical practice in Australia i.e., best sup-
portive care, with delayed use of intravenous C1-INH concentrate if required ad-
ministered in the hospital emergency setting.METHODS:An economic model with
Markov processes was developed to estimate the costs and benefits of self-admin-
istered icatibant compared to current clinical practice in Australia. The model
consisted of four health states (free of HAE attack, cutaneous HAE attack, abdom-
inal HAE attack, laryngeal HAE attack) with patients starting in the attack-free
health state and transitioning to one of the four health states at weekly cycles over
52 weeks. Variables in the model (probability of attack, probability an attack is
treated, duration of attack) were based on evidence from relevant clinical trials and
the wider literature. Utility values were derived from a survey of 201 members of
the Australian general public using a vignette/health state scenario based ap-
proach and standard gamble methodology. Costs were estimated from the per-
spective of the Australian public health care system. RESULTS: Incremental cost
per QALY of self-administered icatibant compared with current clinical practice in
Australia estimated by the model was $71,026. Incremental costs consisted of an
additional $8,864 in icatibant costs relative to C1-INH concentrate costs and a sav-
ing of $105 in the costs of attendances to accident and emergency department. The
majority of the QALY gains were due to the better quality of life whilst in the
attack-free health state, attributed to the “process utility” afforded by having ac-
cess to self-administration and living in the knowledge that when an attack occurs
it can be quickly and easily managed. CONCLUSIONS: This represents a reasonable
level of cost-effectiveness of icatibant in the context of a small patient population
and orphan indication.
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OBJECTIVES: To compare cost-effectiveness of controlled release ropinirole (ROP
CR) with levodopa (LD) and piribedil (PIR) in treatment of Parkinson’s disease in
Poland. METHODS: Lifetime Markov model from Polish public payer perspective
was developed. Two schemes: drug monotherapy (ROP CR vs LD and PIR) and
therapy added to levodopa (ROP CR vs LD) were considered. Effectiveness data were
taken from the systematic review of randomized clinical trials. Utility was modeled
based on the UPDRS values and dyskinesia occurrence. In the model Polish costs of
drugs, qualification, monitoring, hospitalization and dyskinesia treatment were
included. sensitivity analysis were performed for key model’s parameters.
RESULTS: Estimated lifetime QALYs per patient for comparison of monotherapies
were: 8.12 for ropinirole CR, 7.95 for levodopa and 7.89 for piribedil. Differences in
QALYs were statistically significant in favor of ropinirole CR for both comparators.
Average costs per patient were 76,710 PLN for ropinirole CR, 61,180 PLN for
levodopa and 62,860 PLN for piribedil. The ICERs for ropinirole CR were: 94,200 PLN
in comparison to levodopa and 59,780 PLN in comparison to piribedil. Estimated
lifetime QALYs per patient for comparison of ropinirol CR as add-on to levodopa
with levodopa monotherapy in higher doses were: 7.70 for ropinirole CR and 7.16
for levodopa. Differences in QALYs were statistically significant in favor of ropini-
role CR. Average costs per patient were 64,110 PLN for ropinirole CR and 18,420 PLN
for levodopa. The ICERs for comparison of ropinirol CR with levodopa was 84,920
PLN. CONCLUSIONS: Ropinirole is cost-effective in comparison to piribedil and
levodopa in monotherapy, and as add-on to levodopa in comparison to levodopa
monotherapy in higher doses (threshold of three GDP: 102,045 PLN).
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OBJECTIVES:To assess the costs of oral treatment with fingolimod (Gilenya®) com-
pared to intravenous infusion of natalizumab (Tysabri®) in patients with relapse
remitting multiple sclerosis (RRMS) in the The Netherlands. METHODS: A cost-
minimization analysis (CMA) was used to compare the costs of both treatments. In
this analysis drug acquisition costs, drug administration costs, and other costs
related to drug treatment were distinguished. Costs were discounted at 4%, and
incremental model results were presented over a 1, 2, and 10 year time horizon.
The robustness of the model results was determined by means of a number of
deterministic univariate sensitivity analyses and a probabilistic sensitivity analy-
sis. Additionally, a break-even analysis was carried out to determine at what IV
infusion costs a cost neutral outcome would be obtained. RESULTS: When fingoli-
mod was compared to natalizumab, the model predicted discounted incremental
costs of -€1,699 (95%CI: -€2,216;-€946), -€4,094 (95%CI: -€5,017;-€2,625), and -€20,218
(95%CI: -€24,192;-€13,977) over a 1, 2, and 10-year time horizon respectively. Results
of the sensitivity analyses showed that these predictions were most sensitive to
changes in the costs for IV administration of natalizumab. Changing these costs
within a range of €217 and €297 per IV infusion, resulted in cost savings varying
from €15,831 to €24,606 after 10 years. The additional break-even analysis showed
that IV infusion costs needed to be as low as €127 and €73 in order to obtain a cost
neutral result after 1 and 10 years respectively. CONCLUSIONS: The present anal-
ysis showed that treatment with fingolimod resulted in considerable cost savings
compared to natalizumab: €20,218 per RRMS patient in the The Netherlands after
10 years of treatment. The robustness of this estimate was confirmed within the
sensitivity analyses. The conclusions were in line with cost-utility analysis that has
been performed as well, showing cost savings of fingolimod compared to natali-
zumab.
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for stan-
dard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in
patients with uncontrolled partial-onset seizures in the Slovak Republic.
METHODS: The model simulated the treatment pathway of a hypothetical cohort
of 1000 patients over two years from the third party payer perspective in the Slovak
Republic using 2011 pricing. A decision tree was split into four phases of six months
each during which patients can become seizure free, experience a seizure reduc-
tion (responder defined as 50% reduction in seizures), or withdraw due to non-
response. The standard therapy arm included five adjunctive therapies: carbam-
azepine, lamotrigine, levetiracetam, topiramate and valproate. The likelihood of
being in a particular health state has been estimated from clinical trials data. The
cost of outpatient visits, inpatient and emergency department visits were included.
Costs and utility values attached to various health states were taken from the
published literature. RESULTS: Lacosamide adjunctive therapy was associated
with 6730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs),
compared with the standard therapy within the 2-year timeframe. Treatment with
lacosamide was associated with a cost of €103 per seizure avoided, and €18,402 per
QALY gained versus standard therapy over 2 years and falls within acceptable
thresholds of cost-effectiveness in Slovakia. Results calculated for 6-, 12- and 18-
month follow-up showed respective incremental cost-utility ratios of €20,904,
€19,443 and €19,133 and cost per seizure avoided of €276, €127 and €111. Using a
willingness-to-pay threshold of €26,500 per QALY, 83% of the simulations fell below
this value after 2 years of treatment. CONCLUSIONS: Lacosamide was shown to be
a cost-effective adjunctive treatment in patients with uncontrolled partial-onset
epilepsy in the Slovak Republic.
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OBJECTIVES: To assess the cost-utility of oral fingolimod (Gilenya) versus IV natali-
zumab (Tysabri) in active relapsing remitting multiple sclerosis (RRMS) from Bel-
gian healthcare (RIZIV/INAMI  patient), governmental and societal perspectives.
METHODS: A 40-year Markov model was developed containing 20 health states
describing disability severity based upon the Expanded Disability Status Scale
(EDSS): 10 RRMS EDSS states (0-9), 10 secondary progressive MS (SPMS) EDSS states
(0-9) and a death state. Per annual cycle, RRMS patients can remain stable, progress
to a higher RRMS EDSS state or convert to SPMS at a higher EDSS state. Patients
have a fixed annual probability of relapse and death (national age-adjusted mor-
tality). RRMS patients with EDSS score6.5 are eligible for disease modifying ther-
apies (DMTs). Patients with SPMS or EDSS score  6.5 receive best supportive care.
Transition probabilities were based on the natural history of RRMS and the relative
risk of confirmed disability progression and relapse per DMT. Efficacy of natali-
zumab (AFFIRM) and fingolimod (FREEDOMS) was based upon indirect comparison
with adjustment for differences in baseline disease characteristics and demo-
graphics. Belgian costs and utilities obtained from literature were assigned to each
EDSS level and to relapse. DMT monitoring and administration costs were based
upon expert opinion. Costs (3%) and outcomes (1.5%) were discounted. Probabilistic
sensitivity analyses covered variability in efficacy, costs and utilities. RESULTS:
Base-case analyses revealed cost-effectiveness of fingolimod from the health care
perspective and dominance from governmental and societal perspective. The
probability of fingolimod being cost-effective (35,000€/QALY) varied between 64%
and 70%. Results were sensitive to the hazard ratio of disability progression due to
wide and overlapping confidence intervals (indirect treatment comparison). Ex-
cluding uncertainty in this parameter resulted in probabilities of cost-effectiveness
between 81% and 100%.CONCLUSIONS: Treatment of active RRMS with fingolimod
was cost-effective from all payers’ perspectives versus treatment with natali-
zumab.
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FACTORS ASSOCIATED WITH UTILITY AND DISUTILITY VALUES IN RELAPSING
FORM OF MULTIPLE SCLEROSIS (RMS) PATIENTS USING DATA FROM TEMSO, A
TERIFLUNOMIDE PIVOTAL PHASE III TRIAL
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OBJECTIVES: Multiple sclerosis (MS) is a neurodegenerative disease associated
with significant impairments in health related quality of life. This analysis was to
identify patient factors associated with utility in RMS patients and to derive dis-
utility values according to relevant disease stages. METHODS: TEMSO (N1088)
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